Drug Trial Radar · NCT07937605
KC1086 in Combination With Fulvestrant for HR-Positive, HER2-Negative Advanced Breast Cancer
Last checked: Nov 19, 2026Latest source record: Nov 16, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Not yet recruiting
Enrollment
168
Planned (sponsor's estimate)
Start
Nov 2026
Primary completion
Nov 2029
Study completion Nov 2030
Sponsor
- Lead sponsor
- Beijing Konruns Pharmaceutical Co., Ltd.Industry
- Sponsor type
- Industry
- First posted
- Nov 16, 2026
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Non randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this study is to evaluate the safety, efficacy, and pharmacokinetic characteristics of KC1086 in combination with fulvestrant in adults with hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2-) locally advanced or metastatic breast cancer.
Conditions
- HR-positive, HER2-negative Locally Advanced or Metastatic Breast Cancer
Interventions
KC1086Drug
Dosage: 1 mg, 2 mg, or 4 mg; Route: Oral; Frequency: Once daily (QD) under fasting conditions (at least 2 hours before and 1 hour after dosing), 28 days as a cycle.
FulvestrantDrug
Dose: 500 mg. Route: intramuscular injection. Frequency: on Day 1 and Day 15 of Cycle 1, then on Day 1 of each cycle from Cycle 2 onward, 28 days as a cycle.
Everolimus (10 mg QD)Drug
Dose: 10 mg. Route: oral, with or without food. Frequency: once daily, 28 days as a cycle.
ExemestaneDrug
Dose: 25 mg. Route: oral, after a meal. Frequency: once daily, 28 days as a cycle.
KC1086Drug
Dosage: based on the doses selected in Part 1 (high dose and low dose); Route: Oral; Frequency: Once daily (QD) under fasting conditions (at least 2 hours before and 1 hour after dosing), 28 days as a cycle.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Progression-free survival (PFS)Time frame: Baseline to study completion (approximately 48 months)
- Adverse events (AEs)Time frame: Baseline to study completion (approximately 48 months)
Locations
No sites are listed on the registry yet.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.